OSTEOPOROSIS AND BISPHOSPHONATES☆
- 1 January 2003
- journal article
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 85, 8-12
- https://doi.org/10.2106/00004623-200300003-00003
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention TrialJournal of the American Geriatrics Society, 2002
- Who Has Osteoporosis? A Conflict Between Clinical and Public Health PerspectivesJournal of Bone and Mineral Research, 2000
- Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fracturesBone, 1999
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including RasJournal of Bone and Mineral Research, 1998
- Short-Term and Long-Term Fracture Prediction by Bone Mass Measurements: A Prospective StudyJournal of Bone and Mineral Research, 1998
- The Epidemiology of OsteoporosisClinical Orthopaedics and Related Research, 1996
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Journal of Clinical Investigation, 1991
- Reduced Bone Mass in Daughters of Women with OsteoporosisNew England Journal of Medicine, 1989